由于诺和诺德的生产问题,FDA对再生元Eylea HD的决定被推迟FDA Decision on Regeneron’s Eylea HD Delayed Due to Novo Nordisk Manufacturing Issues

动脉网
Aug 21

by Mark Chiang马克·江Share To分享到The U.S. Food and Drug Administration (FDA) has postponed its decision on Eylea HD, a high-dose formulation of the eye treatment developed by Regeneron Pharmaceuticals. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10